Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QEEG Predictors of Response to CBT vs Escitalopram in Depression
NCT00824044Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2008
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of escitalopram in major depressive disorder (MDD) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Hamilton Depression Rating Scale (HAM-D-17) at 12 weeks, Change in Absolute Beta Power in Channel 4 at 12 weeks and 8 more. Started Jul 2008; status: completed.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00824044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00824044.